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The mechanism by which hypohpldemic peroxisome proliferators of the fibrate family induce the hver fatty acid bmdmg protein in liver of rodents 
IS unknown. In order to delineate the level at which this protein is induced. the transcriptional actlvlty of the specific gene encoding for liver fatty 
acid binding protein was measured in isolated hepatocyte nuclei obtained from male Swiss mice dally force-fed durmg 7 days with 400 mg/kg body 
weight bezafibrate. This treatment induced a 4-fold mcrease in the hver fatty acid binding protein transcription rate. Liver fatty acid bmdmg protein 
mRNA level, measured by Northern blot analysis and cytosohc content of this protein, analyzed by immunoblotting, increased concurrently. From 
these results we conclude that the increase in the cytosolic liver fatty acid binding protem level by bezafibrate is due to an enhancement of the 
transcription rate of the liver fatty acid binding protein gene. Whether the transcriptional effect 1s mediated by peroxlsome proliferator-receptor 
remains to be elucidated. 
Liver fatty acid binding protein; Peroxisome proliferator hypohpidemic drug; Peroxisome proliferator activated receptor: Gene regulation 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Liver fatty acid binding protein (L-FABPc) is a cy- 
tosolic 14 kDa protein abundantly expressed in liver 
which binds with a high affinity especially to long chain 
free fatty acids. Several drugs that affect lipid metabo- 
lism cause modifications in the liver L-FABPc concen- 
tration (for review see [l]). In liver, it is well-established 
that peroxisome-proliferating hypolipidemic drugs 
from the fibrate family induce a rise in L-FABPc cy- 
tosolic concentration and in the abundance of its 
mRNA in vivo [2] and in vitro [3]. However, the level 
of this up-regulation is always unknown. In order to 
understand the origin of the high L-FABPc mRNA 
level found in animals treated with these xenobiotics, 
the measurement of relative transcription rate of L- 
FABPc gene was performed by run-on assay in mice 
chronically treated with bezafibrate. In this report, we 
provide the first direct evidence that the increase in 
L-FABPc mRNA in liver results from stimulation of 
L-FABPc gene transcription. 
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Official French regulations (No. 87848 and No. 04727) for the care 
and use of laboratory animals were followed. Male Swiss mice weigh- 
ing 35-38 g were purchased from CED (Centre d’Elevage DCprC) The 
animals were fed ad hbitum a commercial &et (UAR AOCUsine 
d‘Alimentatlon Rationnelle). They were daily force-fed in the morning 
with 400 mg/kg body weight (BW) bezafibrate (Sigma) for days; con- 
trols received in the same way the vehicle alone (200 ~1 of sunflower 
oil). Animals were sacrified m the morning after an overnight fast by 
aortic puncture under light ether anaesthesla. Immediately after sacn- 
fice, one part of the liver was immediately frozen m liquid nitrogen and 
stored at -80°C until required for the RNA extraction. The other part 
was freshly used for supernatant and nuclei preparations Plasma were 
stored at -20°C until required for hpldlc parameters determinations. 
2.2. Molecular probeA 
The I- and L-FABPc cDNA probes were respectively extracted as 
previously described [4] from recombinant plasmids pJG19 [5] and 
pJG418 [6] generously provided by Dr J.I. Gordon (Washington Uni- 
versity. St Louis, MO 63110, USA). These probes cross-react with 
mouse FABPc mRNA [7] Mouse B-actin is a fragment from pOB26 
[8] plasmld encompassing all the sequence of /?-actin mRNA (gift of 
S. Alonso). A 24-mer oligonucleotide specific for rat 18 S rRNA [9], 
but cross-reacting m the mouse. was used to ensure that equivalent 
amounts of RNAs were loaded and transferred. 
2.3. Northern blot analysu 
Total RNA was extracted from liver using phenoVchloroformlLiC1 
method [lo]. Hybridization and washing conditions are described m 
detail elsewhere [4.9]. Autoradiograms were quantified with an auto- 
matic densitometrlc scanner (CS-9000. Shimadzu, Scientific Instru- 
ments). 
2.4. Nuclear run-on transcrrptlon assa) 
Nuclei were freshly prepared as described by Wldnell and Tata [l 11. 
The pelleted nuclei were resuspended at log/ml in ice-cold storage 
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buffer (20 mM Trts pH 8: 75 mM potasstum acetate: 0.5 mM EDTA. 
pH 8; 2 mM DTT; 50% glycerol), frozen in liquid nitrogen m ahquot 
of 200~1 then stored at -80°C until use. In vitro elongation of nascent 
RNA chains was carried out using 2 x 10’ nuclei according to Mezger 
et al. [I21 with some modifications. The nuclei were incubated at 30°C 
during 20 min in transcription mix (20 mM Trts. pH 8; 20% glycerol; 
160 mM potassium acetate; 5 mM MgCl,; 2 mM DTT; plus for each 
reaction, 125 nmol NTP (AGC), 50 units of human placental ribonu- 
clease inhibitor (Amersham), 2 fig creatine phosphokinase; 4 pmol 
phosphocreatme: 0 25 pmol MnClz and 10 pg E. toll tRNA) m pres- 
ence of [a-3’P]UTP (800 Ci/mM Amersham 150 @/reaction). The 
reaction was stopped by addition of 40 units of DNase I (Boehringer) 
and 1OOpg E co/i tRNA (Boehrmger) and incubated for an additional 
15 mm at 37°C. The mixtures were treated with 200 pg of proteinase 
K for 30 min at 37°C. Labeled RNA were purified as described by 
Linial et al [13] then denatured by alcaline hydrolysis. After their 
amplification by polymerase chain reaction (PCR). 1 fig of different 
cDNA fragments (respectively L-FABPc, I-FABPc and p-actm 
cDNA) was denatured and immobilized on Gene Screen membrane 
using an Hoeffer slot blot appartus. The filters were hybridized m 
presence of about IO’ cpm of labeled RNA at 47.5”C for 3 days m 
rotary hybridization incubator. For each experiment, to measure ac- 
curately the volume of mixture corresponding to IO’ cpm. differential 
precipitation of labeled mRNA by the trichloroacetic acid method was 
achieved on aliquot (5 ~1) according to Sambrook et al. [14]. The filters 
were subjected to autoradiography after extensive high strmgency 
washes and RNase treatment [15]. The radioactivity content of the 
signals was assayed m a Packard tricarb scmttllation counter (Packard 
Prtas PLD, Trtcarb) L-FABPc, I-FABPc and p-actm cDNA frag- 
ments were the same as those used as labeled probes m the Northern 
blot analysis. 
2.5. Electrophorem and inmunoblotting procedure 
The high speed supernatants were stored at -20°C until the L- 
FABPc Enhanced Chemtoluminescence (ECL - Amersham) Western 
blot analysts. The rabbit polyclonal antibody to rat L-FABPc was 
generously provided by Dr. J.1. Gordon as well as purified rat L- 
FABPc used as an internal control. After determination of the cy- 
tosohc protein concentration by BCA (Pierce). 2 pg of denatured 
cytosolic proteins were separated by sodium dodecyl sulfate poly- 
acrylamtde gel electrophorests (SDS-PAGE) usmg 12% gels [14] as 
well as 1 pg pure rat L-FABPc in presence of rainbow coloured protein 
molecular weight markers (Amersham). The separated proteins were 
electrophorettcally transferred to Hybond-ECL mtrocellulose mem- 
brane (Amersham) according to manufacturer’s protocol (Biorad). 
The membrane was blocked with 2% bovine serum albumine then 
incubated for 1 h at 25°C with the anti-L-FABPc antibody at a 1: 1000 
dilution. Antigene-antibody complexes were detected by mcubating 
the membrane during 1 h at 25°C with anti-rabbit IgG-horseradish 
peroxidase conjugate (l:lOOO, Amersham) and finally with Amer- 
sham’s ECL reagent for 1 mm 
2.6. Plasma lipids 
The concentrations of total and free cholesterol in plasma of con- 
trols and bezafibrate treated mice were performed using an automatic 
Cobas-bio (Roche). 
2.7. Statistical methods 
Whenever possible, the results were expressed as mean f S.E.M. 
Significance of differences between groups was determined using Stu- 
dent’s t-test. 
3. RESULTS 
3.1. Effect of bezufibrate on body and liver lceights and 
plasma lipids 
AS shown in Table 1, no modification in body weights 
nor in food intakes occurred in mice chronically treated 
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with 400 mg/kg bezafibrate contrary to rats in which 
this protocol triggered a drastic weight loss (data not 
shown). For this reason, we have chosen to perform the 
experiment in mice rather than in rats. The efficiency of 
the treatment was attested by the 1.7-fold increase in 
liver weights and the significant decrease in plasma total 
and free cholesterol (Table I). Indeed. these modifica- 
tions are classically found in rats subjected to fibrate 
treatment [ 161. 
3.2. Enhancement of L-FABPc expression in mouse liver 
under the effect of bexjibrate 
According to the results obtained in rat hepatocytes 
cultured in presence of bezafibrate [3], the L-FABPc 
mRNA abundance was clearly higher in drug treated 
mice (Fig. 1,). After stripping the L-FABPc probe and 
reprobing with 18 S rRNA oligonucleotide, similar hy- 
bridization signals were found in the control and exper- 
imental groups, proving that the increased L-FABPc 
mRNA level was not due to differences in the amounts 
of total RNA sampled (Fig. 1 J. After densitometric 
scanning of autoradiograms, the L-FABPc mRNA level 
was expressed as ratio of hybridized signals between 
L-FABPc probe and 18 S rRNA control probe. In these 
conditions, a 3.5fold increase in the L-FABPc mRNA 
level occurred in the liver of the bezafibrate treated mice 
as compared to controls. By contrast, no modification 
in p-actin mRNA level occurred after bezafibrate treat- 
ment attesting to the specificity of the L-FABPc mRNA 
induction (data not shown). Concurrently, the spec- 
trodensitometric analysis of the Western blot revealed 
that bezafibrate caused on average a 1.7-fold rise in the 
cytosolic L-FABPc amounts (Fig. 12). 
3.3. Influence of bexfibrate on L-FABPc gene tran- 
scription rate 
To determine whether the rise in L-FABPc mRNA 
amounts was the consequence of an increase in the L- 
FABPc synthesis rate or of post-trancriptional events, 
nuclear run-on assays were performed on liver nuclei 
from control and bezafibrate treated mice. In these as- 
says only transcripts which are already initiated are 
faithfully elongated giving an accurate measure of the 
level of transcription at the time of the nuclear isolation 
[13]. Two different experiments were performed in con- 
trols and 3 distinct assays in bezafibrate treated using 
systematically 2 animals per assay in order to verify the 
reproductibility of the results. Since the p-actin mRNA 
levels remained unchanged in mouse liver after bezafi- 
brate treatment, p-actin cDNA was used as control. To 
test the specificity of hybridizations, I-FABPc cDNA 
was spotted in the filters because the I-FABPc is only 
expressed in the intestine. This negative probe allowed 
us to evaluate the non specific radioactivity hybridized 
on the membrane (= background: BG). As shown in 
Fig. 2, the relative transcription rate of the L-FABPc 
gene was substantially higher in the bezafibrate treated 
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Fig. 1. Typical increase in specific L-FABPc mRNA and protein levels triggered by bezafibrate in the mouse liver. Animals were daily force-fed 
during 7 days with 400 mg/kg BW bezafibrate (B) in 0.2 ml of sunflower oil. Controls (0) received the vehicle alone. (1) Northern blot analysis 
of 20 pg of total RNA extracted from livers pooled from 4 animals. To test the amounts of total RNA really sampled, the membrane were 
rehybridtzatton with 18 S rRNA oligonucleotide probe. (2) Western blot analysis of 1 pg of pure L-FABPc and 2 bug of liver cytosolic proteins 
from controls (0) or bezafibrate treated mice (B) Proteins were subjected to SDS-PAGE electrophorests, transferred to nitrocellulose membrane 
and immunostained with anti-rat L-FABPc as described in section 2 by ECL detection. Each sample consisted of liver high-speed supernatants 
pooled from 4 mice. The values indicate the molecular weight relative to Rainbow coloured protein molecular weight markers. 
mice than in the controls which correlated with the 
abundance of its message detected by Northern blot. A 
about 4-fold increase was found on average (Table II). 
The lack of any clear modification in the transcription 
rate of the /5actin gene attested to the validity and the 
specificity of the transcriptional induction of the L- 
FABPc gene by bezafibrate (Fig. 2). 
4. DISCUSSION 
We have performed a daily force-feeding with bezafi- 
brate during 7 days in mice because: (1) this way of 
administration is the best to be sure that animals receive 
the same amount of drug; (2) bezafibrate is very effi- 
ciently absorbed [17]; (3) the maximum induced levels 
of cytosolic L-FABPc are reached after around 1 week 
of fibrate treatment in liver [18]; and (4) no weight loss 
and no decrease in daily food intake is observed in mice 
(Table I) contrary to rats subjected to the same protocol 
(data not shown). 
Our results show that bezafibrate induces a rise in 
L-FABPc mRNA levels with a subsequent increase in 
cytosol L-FABPc content and demonstrate, to our 
knowledge for the first time, that this up-regulation is 
triggered by an enhancement of the transcription rate 
of the L-FABPc gene. This effect is probably due to a 
direct influence of the drug on liver since the bezafibrate 
induces a rise in L-FABPc mRNA abundance in hepa- 
tocytes in culture [3]. Several genes involved in hepatic 
lipid metabolism seem to be sensitive to peroxisome- 
proliferator hypolipidemic drugs. For instance, the 
transcription rate of peroxisomal fatty acyl CoA oxi- 
dase [19] and peroxisomal bifunctional enzyme [ 19-201 
are rapidly increased after fibrate administration. By 
contrast, fenofibrate decreases the transcriptional activ- 
ity of Apo A-I [16]. These coordinate regulations sug- 
gest the existence of a commun control mechanism. 
Table I 
Influence of bezafibrate treatment on body and liver weights and plasma total and free cholesterol (respectively TCS and FCS) concentrations m 
mice 
Experiment Body weight (g) 
Day 0 Day 7 
Liver weight (g) Mean of the dally Plasma lipidic parameters 
food intake (g) 
Day 7 CS (g/l) FCS (g/l) 
0 37.2 + 0.4 36 6 f 0.7 1.74 * 0.09 5.5 f 0.3 0.81 ? 0.05 0.33 * 0.02 
(8) (8) (8) (48) (8) (8) 
B 36.6 f 0.8 35.6 f 1.5 2.95 + 0.21 5.3 f 1.9 0.58 f 0.03 0.25 f 0.02 
(8) (8) (8) (48) (6) (6) 
ns ns *** ns ** * 
Adult male Swiss mice were daily force-fed with 400 mg/kg body weight bezafibrate (B) during 7 days or wtth the vehicle alone (0 2 ml of sunflower 
oil: 0). Liver weights were recorded at the end of the treatment period (day 7). Plasma TCS and FCS were measured as described m sectton 2. 
Values are expressed as mean f S.E.M.; ns = non-sigmficant results; *P < 0.05; **P < 0.01; ***P < 0 001. 
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Fig 2. Effect of bezafibrate on the L-FABPc gene transcriptton in mouse hver. Nuclear run-on assays to evaluate transcription gene actrvrties in 
livers of mace daily force-fed during 7 days with 0.2 ml of sunflower oil (controls’ 0, and 0:) or with 0.2 ml of 400 mg/kg BW bezafibrate in oil 
(B, to B,). Ltver nuclet from 2 mice were pooled for each individual assay. 1 pg of denatured cDNA fragments were bound to nylon membrane 
filters. hybridized to [a-“P]UTP-labeled in vitro elongated transcripts and analyzed by autoradiography. MouseB-actm was used as Internal control 
probe and rat I-FABPc as negative probe (= background). 
Recently, a transacting factor, termed peroxisome pro- 
liferator-actived receptor (PPAR), was identified in 
some target tissues of peroxisome proliferators includ- 
ing liver [2 11. The activated PPAR binds a specific DNA 
sequence, termed peroxisome proliferator responsive el- 
ement (PPRE). found in upstream of the rat acyl CoA 
oxidase gene [22]. It is interesting to observe that a 
PPRE-like sequence is contained in the promotor of the 
rat L-FABPc gene [23]. That might explain the reason 
why bezafibrate increases the transcription rate of L- 
FABPc gene in our experiment. However, lssemann et 
al., using reporter gene constructs and transfection as- 
says in Hepa 1 cells, have recently shown that this puta- 
tive responsive element is unfunctional in the context of 
the natural rat L-FABPc promotor but becomes active 
when it is placed upstream the rabbit P-globin promotor 
[23]. These authors suggest that the failure of the L- 
FABPc gene induction might be due to the high proxi- 
mity of the PPRE-like sequence with the TATA box in 
the rat L-FABPc gene. The apparent discrepancy with 
the results reported here can be explain through several 
hypothesis: (i) the location of the PPRE sequence in the 
mouse L-FABPc gene is different from rat or several 
copies of this sequence are located at different sites 
largely upstream the TATA box; (ii) bezafibrate can 
induce the L-FABPc gene using an other way than the 
PPAR/PPRE complex; or (iii) a co-factor, which lacks 
in Hepa 1 cells but which is naturally present in mouse 
liver is required for PPAR activity. 
Further experiments will be necessary to explore 
these hypothesis and understand the respective roles of 
peroxisome proliferators, PPAR and FABPc in the hy- 
polipidemia triggered by fibrates. 
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(Prof. P. Gambert) for the lipids assays in plasma and M.C. Monnot 
for the photographic prmtmgs This work was supported by grants 
Table II 
Effect of bezafibrate treatment on the transcription rate of the L-FABPc gene in mouse liver 
Experiment A 
Input mRNA 
(x 10h cpm) 
B B/A (8 x lo-‘) 
RNA hybridized L- % of relative transcription Mean transcription rate 
FABPc-BG = (cpm) of L-FABPc gene (arbitrary umts) 
0, 9.6 334- 168= 66 68 
100 
02 13.3 312- 144= 71 5.4 
B, 114 366 - 112 = 254 22.3 
B2 11.4 407 - 119 = 288 25.3 430 
B, 7.0 303- 86=217 31.0 
Relative L-FABPc gene transcription rate m liver from mice daily force-fed during 7 days with 400 mg/kg BW bezafibrate in sunflower oil (B, to 
B,) or with vehicle alone (0.2 ml of sunflower oil: 0, and OZ), Each Individual experiment was performed with hver nuclei pooled from 2 mice. 
I-FABPc cDNA bound radioactivity (= background. BG) was substracted to cpm of specific mRNA hybridized. 
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